C.R. Bard loses patent round, $25M hernia insurance decision

April 1, 2013 by Brad Perriello

The U.S. patent office takes a 1st pass at C.R. Bard's stent graft patent and finds it wanting, while an insurance arbitrator denies a $25 million insurance claim stemming from legal claims against its recalled hernia repair products.

C.R. Bard

C.R. Bard (NYSE:BCR) revealed a 1-2 punch today when it reported another loss in its patent infringement war with W.L. Gore & Assoc. and an adverse insurance decision that could cost it $25 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.